Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LXRX
stocks logo

LXRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.14M
-88.17%
-0.070
-22.22%
5.65M
+347.7%
-0.065
-7.14%
5.75M
-80.08%
-0.070
-800%
Estimates Revision
The market is revising No Change the revenue expectations for Lexicon Pharmaceuticals, Inc. (LXRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 30.28%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+30.28%
In Past 3 Month
Wall Street analysts forecast LXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXRX is 3.97 USD with a low forecast of 1.90 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast LXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXRX is 3.97 USD with a low forecast of 1.90 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.420
sliders
Low
1.90
Averages
3.97
High
6.00
Current: 1.420
sliders
Low
1.90
Averages
3.97
High
6.00
Citi
Buy
upgrade
2025-08-07
Reason
Citi
Price Target
2025-08-07
upgrade
Buy
Reason
Citi raised the firm's price target on Lexicon to $1.90 from $1.20 and keeps a Buy rating on the shares following the Q2 report. The firm also opened a "90-day upside catalyst watch" on the shares. Citi expects full data from the PROGRESS Phase 2b study in Q3 to drive a re-rating of Lexicon, noting that management is bullish on the company's opportunity in pain.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-28
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-07
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-07
Reiterates
Strong Buy
Reason
Needham
Joseph Stringer
Hold
Reiterates
n/a
2025-03-07
Reason
Needham
Joseph Stringer
Price Target
n/a
2025-03-07
Reiterates
Hold
Reason
Piper Sandler
Yasmeen Rahimi
Buy
Maintains
$10 → $6
2025-03-07
Reason
Piper Sandler
Yasmeen Rahimi
Price Target
$10 → $6
2025-03-07
Maintains
Buy
Reason
Piper Sandler analyst Yasmeen Rahimi lowered the firm's price target on Lexicon to $6 from $10 given discontinuation of sotagliflozin in HF and T1D CKD commercialization, while keeping an Overweight rating on the shares. The firm remains bullish on Lexicon given its rich pipeline, which includes three promising assets with recent successful pilavapadin Phase 2b PROGRESS data establishing 10 mg as the ideal Phase 3 dose. Since the 20 mg dose group missed statistical significance, investors seemed to dismiss this asset without recognizing that this dose showed separation vs placebo with good arguments rationalizing the failure to achieve statistical significance. Piper still believes this asset is not only Phase 3-ready but is likely to attract partnership interest.
Leerink Partners
Roanna Ruiz
Buy
to
Hold
Downgrades
$1
2025-03-04
Reason
Leerink Partners
Roanna Ruiz
Price Target
$1
2025-03-04
Downgrades
Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lexicon Pharmaceuticals Inc (LXRX.O) is -5.16, compared to its 5-year average forward P/E of -4.62. For a more detailed relative valuation and DCF analysis to assess Lexicon Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.62
Current PE
-5.16
Overvalued PE
-0.41
Undervalued PE
-8.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.16
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.55
Undervalued EV/EBITDA
-11.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
600.26
Current PS
0.00
Overvalued PS
1999.84
Undervalued PS
-799.31
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LXRX News & Events

Events Timeline

(ET)
2025-11-09
13:18:34
Lexicon Reveals New Clinical Data on Sotagliflozin at AHA Sessions 2025
select
2025-11-06 (ET)
2025-11-06
07:39:12
Lexicon Announces Q3 EPS of 4 Cents, Below Consensus Estimate of 7 Cents
select
2025-10-14 (ET)
2025-10-14
08:19:35
Lexicon Reveals More Pilavapadin Data in DPNP
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-28Benzinga
Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 50 points on Friday.

  • Tilray Brands Inc: Shares of Tilray Brands Inc fell 15% in pre-market trading after announcing a one-for-10 reverse stock split, set to take effect on December 1.

  • Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Inventiva ADR (-7.4%), Anglogold Ashanti PLC (-5.5%), and Lexicon Pharmaceuticals Inc (-5%).

  • Market Movements: SuperX AI Technology Ltd saw a significant drop of 3.9% after a previous surge, while Gold Fields Ltd and Abacus Global Management Inc also reported declines following recent gains.

[object Object]
Preview
1.0
11-25Newsfilter
Lexicon Pharmaceuticals to Participate in Two Major Healthcare Conferences
  • Conference Participation: Lexicon Pharmaceuticals will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3 and the Evercore 8th Annual Healthcare Conference on December 4, showcasing its latest advancements in biopharmaceuticals, which is expected to attract investor and industry attention.
  • Genomic Research: Through its Genome5000™ program, Lexicon has studied nearly 5,000 genes and identified over 100 protein targets with significant therapeutic potential, driving the discovery and development of innovative medicines, highlighting its technological edge in the biopharmaceutical sector.
  • Drug Development Pipeline: Lexicon currently has promising drug candidates in heart failure, neuropathic pain, obesity, cardiology, diabetes, and other indications, indicating a strategic focus on diverse therapeutic solutions to meet market demands.
  • Market Positioning: Lexicon aims to transform patients' lives through precise targeted therapies, and as its drugs gradually reach the market, it is expected to enhance the company's competitiveness and market share in the biopharmaceutical industry.
[object Object]
Preview
2.0
11-17Benzinga
Xpeng, Dell, and Other Major Stocks Decline in Pre-Market Trading on Monday

  • U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures down approximately 0.1% on Monday morning.

  • Xpeng Inc Financial Results: Xpeng Inc reported a quarterly revenue of 20.38 billion Chinese yuan ($2.86 billion), a 101.8% increase year-over-year, but fell short of the $2.87 billion forecast, leading to a 3.6% drop in pre-market trading.

  • Other Stocks Declining: Several stocks experienced declines in pre-market trading, including Plug Power Inc (-6.1%), Lexicon Pharmaceuticals Inc (-6%), and Dell Technologies Inc (-4.7%) after a downgrade by Morgan Stanley.

  • Market Overview: The overall market sentiment appears cautious, with various companies reporting losses and analysts adjusting their ratings, indicating potential challenges ahead.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lexicon Pharmaceuticals Inc (LXRX) stock price today?

The current price of LXRX is 1.42 USD — it has increased 1.43 % in the last trading day.

arrow icon

What is Lexicon Pharmaceuticals Inc (LXRX)'s business?

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.

arrow icon

What is the price predicton of LXRX Stock?

Wall Street analysts forecast LXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXRX is 3.97 USD with a low forecast of 1.90 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lexicon Pharmaceuticals Inc (LXRX)'s revenue for the last quarter?

Lexicon Pharmaceuticals Inc revenue for the last quarter amounts to 14.18M USD, increased 710.40 % YoY.

arrow icon

What is Lexicon Pharmaceuticals Inc (LXRX)'s earnings per share (EPS) for the last quarter?

Lexicon Pharmaceuticals Inc. EPS for the last quarter amounts to -0.04 USD, decreased -77.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lexicon Pharmaceuticals Inc (LXRX)'s fundamentals?

The market is revising No Change the revenue expectations for Lexicon Pharmaceuticals, Inc. (LXRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 30.28%.
arrow icon

How many employees does Lexicon Pharmaceuticals Inc (LXRX). have?

Lexicon Pharmaceuticals Inc (LXRX) has 103 emplpoyees as of December 05 2025.

arrow icon

What is Lexicon Pharmaceuticals Inc (LXRX) market cap?

Today LXRX has the market capitalization of 514.21M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free